Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000810382 | SCV000950578 | pathogenic | Neurofibromatosis, type 1 | 2022-09-06 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln912*) in the NF1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 654419). This premature translational stop signal has been observed in individual(s) with NF1-related conditions (PMID: 21520333, 34489640). |
Ambry Genetics | RCV002319114 | SCV001177392 | pathogenic | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2018-06-21 | criteria provided, single submitter | clinical testing | The p.Q912* pathogenic mutation (also known as c.2734C>T), located in coding exon 21 of the NF1 gene, results from a C to T substitution at nucleotide position 2734. This changes the amino acid from a glutamine to a stop codon within coding exon 21. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Genome- |
RCV000810382 | SCV002561800 | pathogenic | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing |